China, Nov. 13 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Cadonilimab Combined with Isatuximab (Anti-CD38 Monoclonal Antibody) and XELOX as First-Line Treatment for HER2-Negative, Claudin18.2-Negative Advanced Gastric Adenocarcinoma: A Single-Arm, Phase II Clinical Study Protocol'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600136602
Registration Time: 2026/11/12
Type: Interventional study
Primary Sponsor: Renmin Hospital of Wuhan University
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=351969
Published by HT Digital Content Services with permission from Health Daily Digest....